10:59 AM EST, 02/11/2025 (MT Newswires) -- (Updates with recent share movement in the headline and first paragraph.)

Travere Therapeutics ( TVTX ) shares were up over 13% in recent Tuesday trading after the company said it has completed a meeting with the US Food and Drug Administration and plans to submit a supplemental new drug application for approval of Filspari as a potential treatment for focal segmental glomerulosclerosis, a rare kidney disorder.

The application is based on the drug's mid-stage and late-stage studies and is expected to be submitted late in Q1, the biopharmaceutical company said.

Price: 24.00, Change: +2.90, Percent Change: +13.74